司美格鲁肽改善非酒精性脂肪肝患者肝脏脂肪但未改善肝脏硬度
48周时两组肝脏硬度变化无显著差异,但司美格鲁肽组肝脏脂肪减少显著优于安慰剂,且肝酶、体重和HbA1c下降。
要点
- 司美格鲁肽0.4mg每日皮下注射未显著改善48周时肝脏硬度。
- 司美格鲁肽显著降低肝脏脂肪含量,更多患者达到肝脂肪减少≥30%。
- 司美格鲁肽还降低肝酶、体重和HbA1c,提示代谢改善。
核心结论
- 司美格鲁肽与安慰剂相比未显著改变非酒精性脂肪肝患者的肝脏硬度,但显著减少肝脏脂肪并改善肝酶和代谢指标。
主要发现
- 48周时肝脏硬度变化两组无显著差异(估计治疗比0.96,95%CI 0.89-1.03,P=0.2798),24周和72周亦无显著差异。
- 司美格鲁肽组肝脏脂肪减少显著优于安慰剂,24、48、72周的估计治疗比分别为0.70(95%CI 0.59-0.84,P=0.0002)、0.47(95%CI 0.36-0.60,P<0.0001)、0.50(95%CI 0.39-0.66,P<0.0001)。
- 司美格鲁肽组在24、48、72周达到肝脂肪含量减少≥30%的患者比例显著更高(均P<0.001)。
- 司美格鲁肽组还观察到肝酶、体重和HbA1c下降。
临床怎么用
- 对于非酒精性脂肪肝患者,司美格鲁肽0.4mg每日皮下注射可显著减少肝脏脂肪并改善代谢指标,但未能改善肝脏硬度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glucagon-like peptide-1 receptor agonists may be a treatment option in patients with non-alcoholic fatty liver disease (NAFLD). AIMS: To investigate the effects of semaglutide on liver stiffness and liver fat in subjects with NAFLD using non-invasive magnetic resonance imaging (MRI) methods. METHODS: This randomised, double-blind, placebo-controlled trial enrolled subjects with liver stiffness 2.50-4.63 kPa by magnetic resonance elastography (MRE) and liver steatosis ≥10% by MRI proton density fat fraction (MRI-PDFF). The primary endpoint was change from baseline to week 48 in liver stiffness assessed by MRE. RESULTS: Sixty-seven subjects were randomised to once-daily subcutaneous semaglutide 0.4 mg (n = 34) or placebo (n = 33). Change from baseline in liver stiffness was not significantly different between semaglutide and placebo at week 48 (estimated treatment ratio 0.96 (95% CI 0.89, 1.03; P = 0.2798); significant differences in liver stiffness were not observed at weeks 24 or 72. Reductions in liver steatosis were significantly greater with semaglutide (estimated treatment ratios: 0.70 [0.59, 0.84], P = 0.0002; 0.47 [0.36, 0.60], P < 0.0001; and 0.50 [0.39, 0.66], P < 0.0001) and more subjects achieved a ≥ 30% reduction in liver fat content with semaglutide at weeks 24, 48 and 72, (all P < 0.001). Decreases in liver enzymes, body weight and HbA1c were also observed with semaglutide. CONCLUSIONS: The change in liver stiffness in subjects with NAFLD was not significantly different between semaglutide and placebo. However, semaglutide significantly reduced liver steatosis compared with placebo which, together with improvements in liver enzymes and metabolic parameters, suggests a positive impact on disease activity and metabolic profile. ClinicalTrials.gov identifier: NCT03357380.
引用
- Flint A, Andersen G, Hockings P, et al. Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. Aliment Pharmacol Ther. 2021. PMID: 34570916. doi:10.1111/apt.16608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。